2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y1
Asia
Platelet aggregation inhibitors
comorbidity
consensus
dual antiplatelet therapy
myocardial ischaemia
Journal
European cardiology
ISSN: 1758-3764
Titre abrégé: Eur Cardiol
Pays: England
ID NLM: 101574780
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
13
07
2021
accepted:
04
09
2021
entrez:
24
11
2021
pubmed:
25
11
2021
medline:
25
11
2021
Statut:
epublish
Résumé
Advanced age, diabetes, and chronic kidney disease not only increase the risk for ischaemic events in chronic coronary syndromes (CCS) but also confer a high bleeding risk during antiplatelet therapy. These special populations may warrant modification of therapy, especially among Asians, who have displayed characteristics that are clinically distinct from Western patients. Previous guidance has been provided regarding the classification of high-risk CCS and the use of newer-generation P2Y
Identifiants
pubmed: 34815751
doi: 10.15420/ecr.2021.35
pmc: PMC8591619
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e43Informations de copyright
Copyright © 2021, Radcliffe Cardiology.
Déclaration de conflit d'intérêts
Disclosure: This work was funded through the Asian Pacific Society of Cardiology (APSC) with unrestricted educational grants from Abbott Vascular, Amgen, AstraZeneca, Bayer and Roche Diagnostics. JWCT reports honoraria from AstraZeneca, Bayer, Amgen, Medtronic, Abbott Vascular, Biosensors, Alvimedica, Boehringer Ingelheim and Pfizer; research and educational grants from Medtronic, Biosensors, Biotronik, Philips, Amgen, AstraZeneca, Roche, Otsuka, Terumo and Abbott Vascular; and consulting fees from Elixir and CSL Behring; and is on the European Cardiology Review editorial board; this did not influence peer review. JA reports honoraria from AstraZeneca, Daiichi Sankyo, Bayer and Sanofi; and grants/grants pending from Daiichi Sankyo. DPC reports consulting fees from APSC; support for travel to meetings for the study or otherwise from APSC; grants/grants pending from Roche Diagnostics; payment for development of educational presentations including service on speakers’ bureaus from AstraZeneca. JD reports honoraria from Bayer and Pfizer. CTC reports honoraria from Abbott Vascular, AstraZeneca, Boston Scientific, Biotronik, Biosensors, Medtronic; consulting and ad boards from AstraZeneca, Boston Scientific; and research and educational support from AstraZeneca, Eli Lilly. AH reports consulting fee or honorarium from AstraZeneca. MC reports consulting fee or honorarium from AstraZeneca. AYYF reports honoraria and educational support from AstraZeneca. BK reports consulting fee or honorarium from AstraZeneca, Abbott, IE Menarini, Daiichi Sankyo, Sanovel and ARIS. UB reports honoraria from Amgen and AstraZeneca. All other authors have no conflicts of interest to declare.
Références
Am Heart J. 2018 Mar;197:77-84
pubmed: 29447787
Cardiovasc Drugs Ther. 2019 Oct;33(5):523-532
pubmed: 31549262
Circulation. 2020 Nov 3;142(18):1700-1708
pubmed: 32867508
JAMA. 2019 Jun 25;321(24):2428-2437
pubmed: 31237645
Br J Clin Pharmacol. 2018 Jan;84(1):88-96
pubmed: 28921624
Lancet. 2015 Aug 15;386(9994):702-13
pubmed: 26334162
Arterioscler Thromb Vasc Biol. 2010 Dec;30(12):2400-7
pubmed: 21071689
Lancet. 2012 Nov 10;380(9854):1662-73
pubmed: 23013602
Circ Cardiovasc Interv. 2020 Sep;13(9):e009177
pubmed: 32838554
J Clin Epidemiol. 2011 Apr;64(4):401-6
pubmed: 21208779
Circulation. 2016 Sep 6;134(10):e123-55
pubmed: 27026020
EuroIntervention. 2016 Nov 20;12(10):1239-1245
pubmed: 26606735
N Engl J Med. 2019 Nov 21;381(21):2032-2042
pubmed: 31556978
Cardiovasc Diagn Ther. 2018 Oct;8(5):594-609
pubmed: 30498684
Lancet. 2018 Jan 6;391(10115):41-50
pubmed: 29102362
Am Heart J. 2016 Dec;182:125-134
pubmed: 27914492
N Engl J Med. 2019 Oct 3;381(14):1309-1320
pubmed: 31475798
Eur J Intern Med. 2017 Sep;43:28-35
pubmed: 28400078
Angiology. 2018 Jul;69(6):548-554
pubmed: 28905638
J Am Coll Cardiol. 2010 Jun 8;55(23):2556-66
pubmed: 20513595
Clin Kidney J. 2020 May 03;13(5):803-812
pubmed: 33125004
J Am Coll Cardiol. 2013 Aug 13;62(7):577-83
pubmed: 23747759
J Thromb Haemost. 2016 Jan;14(1):57-64
pubmed: 26512550
J Am Coll Cardiol. 2007 May 15;49(19):1982-8
pubmed: 17498584
JACC Cardiovasc Interv. 2009 Aug;2(8):748-57
pubmed: 19695543
J Geriatr Cardiol. 2017 Feb;14(2):93-99
pubmed: 28491083
Thromb Haemost. 2019 Jan;119(1):149-162
pubmed: 30597509
Lancet. 2017 Jul 29;390(10093):490-499
pubmed: 28622955
J Geriatr Cardiol. 2019 Feb;16(2):103-113
pubmed: 30923541
Circ Cardiovasc Interv. 2015 Jun;8(6):e001683
pubmed: 26056248
Int J Cardiol. 2017 Jan 15;227:1-7
pubmed: 27846456
Eur Cardiol. 2021 Jun 18;16:e26
pubmed: 34249148
Clin Res Cardiol. 2020 Jul;109(7):930-943
pubmed: 31925529
Circ Cardiovasc Interv. 2018 Mar;11(3):e006144
pubmed: 29870385
Lancet. 2017 Mar 11;389(10073):1025-1034
pubmed: 28290994
Heart. 2021 Mar 23;:
pubmed: 33758008
Thromb Haemost. 1996 Sep;76(3):312-21
pubmed: 8883263
Eur Heart J. 2018 Jan 14;39(3):213-260
pubmed: 28886622
J Am Coll Cardiol. 2016 May 17;67(19):2224-2234
pubmed: 27079334
ASAIO J. 1994 Jan-Mar;40(1):49-55
pubmed: 8186492
Hematol J. 2002;3(1):38-42
pubmed: 11960394
Nephron. 1987;45(3):207-10
pubmed: 3574570
JACC Cardiovasc Interv. 2009 Jan;2(1):37-45
pubmed: 19463396
Lancet. 2018 Sep 15;392(10151):940-949
pubmed: 30166073
Semin Thromb Hemost. 2004 Oct;30(5):579-89
pubmed: 15497100
Eur Heart J. 2021 Apr 7;42(14):1289-1367
pubmed: 32860058
J Clin Invest. 1983 Mar;71(3):762-8
pubmed: 6298281
Lancet. 2019 Sep 28;394(10204):1169-1180
pubmed: 31484629
Eur Heart J. 2010 May;31(10):1257-65
pubmed: 20181681
EuroIntervention. 2020 Apr 03;15(18):e1605-e1614
pubmed: 31845894
J Am Heart Assoc. 2021 Jan 5;10(1):e018366
pubmed: 33345567
Eur Heart J. 2021 Aug 23;:
pubmed: 34423374
Eur Heart J. 2020 Jan 14;41(3):407-477
pubmed: 31504439
Clin J Am Soc Nephrol. 2017 Feb 7;12(2):262-271
pubmed: 28174317
Lancet. 2020 Apr 25;395(10233):1374-1381
pubmed: 32334703
J Saudi Heart Assoc. 2017 Jul;29(3):195-202
pubmed: 28652673
Eur Heart J. 2017 Apr 7;38(14):1048-1055
pubmed: 28329300
J Pers Med. 2021 Mar 21;11(3):
pubmed: 33801161
Circulation. 2001 Jan 23;103(3):363-8
pubmed: 11157686
Clin Pharmacol Ther. 2011 Aug;90(2):328-32
pubmed: 21716271
Lancet. 2010 Jun 26;375(9733):2215-22
pubmed: 20609967
JACC Cardiovasc Interv. 2011 Sep;4(9):1011-9
pubmed: 21939942
Am J Cardiol. 2011 Apr 15;107(8):1136-43
pubmed: 21324428
J Thromb Thrombolysis. 2016 Jul;42(1):77-83
pubmed: 26831482
BMJ Open. 2012 Feb 16;2(1):e000540
pubmed: 22344538
N Engl J Med. 2015 May 7;372(19):1791-800
pubmed: 25773268
Lancet. 2021 Jun 26;397(10293):2487-2496
pubmed: 34010616
Eur Heart J. 2020 Jan 14;41(3):347-356
pubmed: 31504434
Eur Cardiol. 2021 Mar 02;16:e02
pubmed: 33708263
Lancet. 2018 Mar 31;391(10127):1274-1284
pubmed: 29544699
Circulation. 2009 Apr 14;119(14):1873-82
pubmed: 19332461
Eur Heart J. 2019 Jun 21;40(24):1963-1970
pubmed: 30851041
JAMA. 2019 Jun 25;321(24):2414-2427
pubmed: 31237644
JACC Cardiovasc Interv. 2013 Sep;6(9):897-904
pubmed: 24050858
J Am Coll Cardiol. 2015 Sep 15;66(11):1209-1220
pubmed: 26361150
JAMA. 2016 Apr 26;315(16):1735-49
pubmed: 27022822